Thalidomide and thrombosis

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue SUPPL. 1, 2003, Pages 15-18

  Rodeghiero, Francesco ^a   Elice, Francesca ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; THALIDOMIDE; WARFARIN;

ANGIOGENESIS; ANTICOAGULANT THERAPY; CANCER CHEMOTHERAPY; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACTIVITY; HUMAN; HYPERCOAGULABILITY; NEUROPATHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; TERATOGENESIS; VEIN THROMBOSIS;

HUMANS; INCIDENCE; NEOPLASMS; THALIDOMIDE; THROMBOPHILIA; THROMBOSIS;

EID: 0345359901     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073282     Document Type: Conference Paper

References (22)

1. Pitini V, Teti D, Arrigo C, Aloi G, Righi M: Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF. Br J Haematol 2002;119:268-288.
2. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N: Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002;16(1):1-6.
3. Horne MK 3rd, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL: Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 2003;23(3):315-318.
4. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM: A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 2002;95(8):1629-1636.
5. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98(2):492-494.
6. Bennett CL, Schumok GT, Kwaan HC, Raisch DW: High incidence of thalidomide-associated deep vein thrombosis and pulmonary emboli when chemotherapy is also administered (abstract). Blood 2001;98:863a.
7. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98(5):1614-1615.
8. Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J: Thromboembolic events during treatment with thalidomide. Blood 2002;99(11):4247-4248.
9. Moehler TM, Schlenzka J, Kasper B, Neben K, Egerer G, Ho AD, Goldschmidt H: Low incidence of deep venous thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy (abstract). Blood 2002;100(11):5136.
10. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood 2002;100(4):1168-1171.
11. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20(21):4319-4323.
12. Cavo M, Zamagni E, Cellini C, Tosi P, Cangini D, Cini M, Valdre L, Palareti G, Masini L, Tura S, Baccarani M: Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002;100(6):2272-2273.
13. Osman K, Comenzo R, Rajkumar SV: Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001;344(25):1951-1952.
14. Oakervee H, Brownell A, Cervi P, Grant I, Rahemtulla A, Child A, Lloyd L, Samson D, Cavenagh JD: A study of the safety and efficacy of thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) in the treatment of younger patients with multiple myeloma: A UK Myeloma Forum Pilot Study. Br J Haematol 2002;117(suppl 1):65.
15. Cavenagh JD, Oakervee H, UK Myeloma Forum and the BCSH Haematology/Oncology Task Forces: Thalidomide in multiple myeloma: Current status and future prospects. Br J Haematol 2003;120(1):18-26.
16. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G: Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002;13(3):187-192.
17. Ward CM, Yen T, Harvie R, Pavlakis N: Elevated levels of factor VIII and von Willebrand factor after thalidomide treatment for malignancy: Relationship to thromboembolic events (abstract). Hematol J 2003;4(suppl 1):365.
18. Auwerda HJA, Leebeek FW, Schoester M, Sonneveld P: Progressive multiple myeloma is associated with increased serum VEGF (abstract). Blood 2002;100(11):5059.
19. Weber D, Ginsberg C, Walker P, Oholendt M, Rankin K, Gavino M, Delasalle K, Alexanian R, et al: Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone(TD) (abstract). Blood 2002;100(11):787.
20. Kaushal V, Kaushal GP, Anaissie EJ, Kurylo P, Kohli M, Fink LM, Mehta P: Thalidomide-induced coagulopathy: Evidence for an indirect effect on endothelium (abstract). Blood 2002;100(11):3771.
21. Kaushal V, Kaushal GP, Mlekaveri S, Kohli M, Fink L, Mehta P: Thalidomide protects endothelial cells from doxorubicin-induced injury but alters cell morphology (abstract). Hematol J 2003;4(suppl 1):357.
22. Zangari M, Barlogie B, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, van Rhee F, Anaissie E, Fassas A, Fink L, Tricot G: Effect of anticoagulation on development and recurrence of deep vein thrombosis (DVT) in multiple myeloma patients treated with chemotherapy and thalidomide (Total therapy II) (abstract). Hematol J 2003;4(suppl 1):358.